Clinical Trials
156 trialsGyneRep
University Health Network, Toronto
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
EWOC-1
Hospices Civils de Lyon
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Zhejiang Cancer Hospital
SALVOVAR
ARCAGY/ GINECO GROUP
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Wake Forest University Health Sciences
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
PRESELECT-0
The University of Hong Kong
Preselect-1
The University of Hong Kong
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Seoul National University Hospital
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
EUDARIO
Universitaire Ziekenhuizen KU Leuven
SCENIC
The University of Hong Kong
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Tongji Hospital
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
Loma Linda University
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Qilu Hospital of Shandong University
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Anhui Provincial Cancer Hospital
CRS/HIPEC
Mercy Medical Center
ANITA
Grupo Español de Investigación en Cáncer de Ovario
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
Endeavor Health
OVMET
University Medical Center Groningen
ACTOv
University College, London
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Albert Einstein College of Medicine
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Medical College of Wisconsin
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
ATHOC
University Medical Centre Ljubljana
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
MITO-8
National Cancer Institute, Naples
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
MYCA
ARCAGY/ GINECO GROUP
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
SELENIUM
Seoul National University Hospital
MOGCT-01
Shandong University
SCST-01
Shandong University
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
MITO-7
National Cancer Institute, Naples
MITO16/MANGO-2
National Cancer Institute, Naples